A Phase 3 interventional study of Azacitidine in Myelodysplastic Syndromes, sponsored by Celgene. Completed at 22 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-14.
Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 130 studies testing azacitidine in Myelodysplastic Syndromes — 13 open to participants now, 25 under way, 3 of them phase 3. Azacitidine · Myelodysplastic Syndromes.
Among the 130 studies testing azacitidine in Myelodysplastic Syndromes, this one is the 54th largest by enrollment of the 126 interventional ones that give a count, is one of 4 that started in 2007, is one of 9 in phase 3, and was the 40th registered.
1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 324 are open to participants now.
Browse Myelodysplastic Syndromes studies →13 of the 130 studies testing azacitidine in Myelodysplastic Syndromes are open now, in 12 countries. Recruiting first, the newest first:
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Sites in China
Ages 18–70
City of Hope Medical Center · Sites in United States
Ages 18–75
Medical College of Wisconsin · Sites in United States
Ages 18+
Institut de Recherches Internationales Servier · Sites in United States, Australia, Brazil and 7 more countries
Ages 18+
Beijing 302 Hospital · Sites in China
Ages 18–70
By country, each count listing its studies:
Azacitidine: first FDA approval 2004 (VIDAZA), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 264 Myelodysplastic Syndromes studies recruiting now, 167 (63%) set no upper age limit and 70 (27%) stop at 75 or younger; 57 take children under 18; 17 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
130 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 50 · Phase 2 86 · Phase 3 12 · Phase 4 3
First in 2000; this study’s year is marked. 4 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 40 is close to the median of 40 across 1,611 interventional studies indexed under Myelodysplastic Syndromes.
Median enrollment 38 across the 126 interventional studies. Of the 88 that completed or were terminated, 42 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 130 have an industry lead sponsor. The 10 most frequent:
This study is registered under Celgene, one of the names counted as Bristol-Myers Squibb. Under that name alone:
Celgene is the lead sponsor of 428 studies on the registry; 12 are open to participants now.
Of its 104 completed or terminated interventional studies of FDA-regulated products, 30 (29%) have results posted.
75 studies in Myelodysplastic Syndromes by Bristol-Myers Squibb: 4 open now, 9 under way, 5 of them phase 3. Of 63 finished, 20 (32%) have results posted.
Among the 75 studies in Myelodysplastic Syndromes by Bristol-Myers Squibb, this one is the 26th largest by enrollment of the 46 interventional ones that give a count, is one of 5 that started in 2007, is one of 11 in phase 3, and was the 23rd registered.
Bristol-Myers Squibb’s Myelodysplastic Syndromes studies by the year they started, since 2001.
9 of the studies testing azacitidine in Myelodysplastic Syndromes that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06465953Phase 3Institut de Recherches Internationales ServierIvosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation | 2027-11-01 |
| NCT05788679Karolinska University HospitalA Study Using Subject-specific MRD to Adopt Treatment After HSCT for Subjects With MDS | 2026-12 |
| NCT00392353National Cancer Institute (NCI)Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia | 2026-12-31 |
| NCT06502145Medical College of WisconsinIadademstat With Hypomethylating Agent in Patients With Myelodysplastic Syndrome | 2026-12-31 |
| NCT03862157M.D. Anderson Cancer CenterAzacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | 2027-01-31 |
Add all 9 to your calendar (.ics) → With an account.
Among the 130 studies testing azacitidine in Myelodysplastic Syndromes, from their registry updates:
Among Bristol-Myers Squibb’s 75 in Myelodysplastic Syndromes:
This tab as a report to print or save as PDF → With an account.
At the conclusion of study AZA PH GL 2003 CL 001 (NCT00071799), eligible participants could be enrolled in an optional extension phase in order to continue treatment with azacitidine until it became commercially available; the continued treatment was for ethical and safety reasons only and not to provide additional efficacy data.
At the conclusion of study AZA PH GL 2003 CL 001 (NCT00071799), eligible participants could be enrolled in an optional extension phase in order to continue treatment with azacitidine until it became commercially available; the continued treatment was for ethical and safety reasons only and not to provide additional efficacy data.
During the extension phase, participants were treated based on 28-day cycles and monitored for hematologic, nonhematologic, and renal toxicities. Recommended monitoring procedures included complete blood count with differential and platelets at least once each cycle prior to dosing and as needed, bone marrow biopsy and aspirate as clinically indicated, and additional tests or more frequent monitoring at the investigator's discretion based on the patient's clinical status. The azacitidine dose could be modified for toxicities. Laboratory data were not collected during the extension phase.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Azacitidine (study drug) plus best supportive care.
Drug: Azacitidine
Azacitidine was injected subcutaneously (SC) for 7 days. The 7-day dosing was repeated every 28 days with dose adjustments allowed. The initial dose during the primary study was 75mg/m\^2/day.
Also known as: AZA
Number of Participants in Different Categories of Treatment Emergent Adverse Events for the Extension Period
Participant counts for a variety of subsets of treatment emergent adverse events (TEAEs)during the extension study period (43-68 months). Subsets include participants counts for serious TEAEs, serious TEAEs that the investigator evaluated as releated to treatment, TEAEs leading to discontinuation of therapy, or a dose reduction, or a dose interruption.
Time frame: 43- 68 months
| Milestone | Azacitidine |
|---|---|
| Started | 40 |
| Completed | 0 |
| Not completed | 40 |
| Withdrew: Death | 7 |
| Withdrew: Withdrawal by subject | 2 |
| Withdrew: No longer receiving clinical benefit | 17 |
| Withdrew: Program closed | 5 |
| Withdrew: Sponsor decision | 4 |
| Withdrew: Started additional treatment | 1 |
| Withdrew: Nci ctc grade 3 or 4 toxicity | 1 |
| Withdrew: Myocardial infarction | 1 |
| Withdrew: Bone marrow transplant | 1 |
| Withdrew: Transformation to aml | 1 |
Participant counts for a variety of subsets of treatment emergent adverse events (TEAEs)during the extension study period (43-68 months). Subsets include participants counts for serious TEAEs, serious TEAEs that the investigator evaluated as releated to treatment, TEAEs leading to discontinuation of therapy, or a dose reduction, or a dose interruption.
| participants | Azacitidine |
|---|---|
| Participants with >=1 treatment emergent AE (TEAE) | 39 |
| Participants with >=1 treatment related TEAE | 27 |
| Participants with >=1 serious TEAE | 20 |
| Participants with >=1 serious trtment related TEAE | 5 |
| Participants w TEAE leading to discontinued treat | 15 |
| Participants w TEAE leading to dose reduction | 4 |
| Participants w TEAE leading to dose interruption | 15 |
Collected over Extension study covering 43- 68 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Azacitidine | — | 20/40 (50%) | 36/40 (90%) |
| Event | Azacitidine |
|---|---|
| Myelodysplastic syndromeNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 4/40 |
| AnaemiaBlood and lymphatic system disorders | 2/40 |
| PneumoniaInfections and infestations | 2/40 |
| Febrile neutropeniaBlood and lymphatic system disorders | 1/40 |
| ThrombocytopeniaBlood and lymphatic system disorders | 1/40 |
| Acute myocardial infarctionCardiac disorders | 1/40 |
| Angina pectorisCardiac disorders | 1/40 |
| Cardiac arrestCardiac disorders | 1/40 |
| Cardiac failureCardiac disorders | 1/40 |
| Cardiac failure congestiveCardiac disorders | 1/40 |
| Event | Azacitidine |
|---|---|
| ThrombocytopeniaBlood and lymphatic system disorders | 17/40 |
| NeutropeniaBlood and lymphatic system disorders | 13/40 |
| AnaemiaBlood and lymphatic system disorders | 11/40 |
| DiarrhoeaGastrointestinal disorders | 10/40 |
| Injection site reactionGeneral disorders | 8/40 |
| PyrexiaGeneral disorders | 7/40 |
| NauseaGastrointestinal disorders | 6/40 |
| FatigueGeneral disorders | 6/40 |
| Oedema peripheralGeneral disorders | 5/40 |
| NasopharyngitisInfections and infestations | 5/40 |
| Age, Continuous(years) | Azacitidine |
|---|---|
| Mean | 68.6 ± 8.23 |
| Sex: Female, Male(Participants) | Azacitidine |
|---|---|
| Female | 8 |
| Male | 32 |
| Race/Ethnicity, Customized(participants) | Azacitidine |
|---|---|
| Caucasian | 40 |
| French-American-British (FAB) Classification(participants) | Azacitidine |
|---|---|
| Refractory anemia with excess blasts (RAEB) | 27 |
| RAEB in transformation | 10 |
| Modified chronic myelomonocytic leukemia | 1 |
| Acute myeloid leukemia | 1 |
| Myeloproliferative disease | 1 |
| World Health Organization (WHO) Classification(participants) | Azacitidine |
|---|---|
| Refractory anemia with excess blasts - 1 | 5 |
| Refractory anemia with excess blasts - 2 | 22 |
| Chronic myelomonocytic leukemia - 1 (CMMoL-1) | 0 |
| Chronic myelomonocytic leukemia - 2 (CMMoL-2) | 2 |
| Acute myeloid leukemia | 11 |
| International Prognostic Scoring System (IPSS)(participants) | Azacitidine |
|---|---|
| Intermediate risk level 1 (0.5-1.0) | 1 |
| Intermediate risk level 2 (1.5-2.0) | 21 |
| High risk (2.5-3.5) | 14 |
| Not applicable | 2 |
| Indeterminate | 2 |
Ran from Apr 2007 to primary completion in Sep 2009, 29 months.
Results were first posted in Sep 2010, 1 year after primary completion.
Of 26 industry-sponsored phase 3 interventional studies under Myelodysplastic Syndromes, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 52. This study's 29 months is below that.
Counting every sponsor, half of 45 studies reached it within 50 months; a quarter within 38 and three quarters within 95.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Azacitidine